| Description |
Labelled Bexarotene. Bexarotene (Targretin) is an antineoplastic agent approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) (early 2001) for use as a treatment for cutaneous T cell lymphoma (CTCL). It is a third-generation retinoid. It inhibits cell cycle progression, induces apoptosis, prevents or overcomes multidrug resistance through multidrug resistance protein 1 (MDR1), and blocks angiogenesis and metastasis, making it a promising chemopreventive agent against cancer. |
| Synonyms |
Bexarotene-d4; 4-(1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl)benzoic-2,3,5,6-d4 Acid; 4-[1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]-benzoic Acid-d4; LGD1069 D4; Targretin-d4; Targretyn-d4 |
| IUPAC Name |
2,3,5,6-tetradeuterio-4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid |
| Related CAS |
153559-49-0 (unlabelled)
|
| Canonical SMILES |
CC1=CC2=C(C=C1C(=C)C3=CC=C(C=C3)C(=O)O)C(CCC2(C)C)(C)C |
| InChI |
InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26)/i7D,8D,9D,10D |
| InChI Key |
NAVMQTYZDKMPEU-ULDPCNCHSA-N |
| Purity |
≥95%; ≥99% atom D |
| Density |
1.0 g/cm3 (Predicted) (unlabeled) |
| Solubility |
Soluble in Chloroform (Slightly), Methanol (Slightly) |
| Appearance |
Crystalline Solid |
| Storage |
Store at -20°C |
![Bexarotene-[d4]](https://resource.bocsci.com/structure/2182068-00-2.gif)
